Lung cancer response to gefitinib, then erlotinib, then gefitinib again

Journal of Thoracic Oncology

Volumn 3, Issue 9, 2008, Pages 1077-1078

  Wong, Alvin S ^a   Seto, Kar Yin ^a   Chin, Tan Min ^a   Soo, Ross A ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG SENSITIVITY; DRUG WITHDRAWAL; EXON; FEMALE; FEMUR FRACTURE; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG METASTASIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SURVIVAL TIME; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT RESPONSE; DRUG ANTAGONISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 58149132001     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318183afb0     Document Type: Letter

References (5)

1. Wong AS, Soong R, Seah SB, et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3:400-404.
2. Yokouchi H, Yamazaki K, Kinoshita I, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7:51. Available at: http://www.biomedcentral.com/ 1471-2407/7/51.
3. Cho BC, Im CK, Park MS, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-2533.
4. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-57.
5. Grossi F, Brianti A, Defferrari C, Loprevite M, Catania G, Pronzato P. Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(June 20 Supplement):18138.